Changeflow GovPing Pharma & Drug Safety Single domain antibodies for cancer therapy, In...
Routine Notice Added Final

Single domain antibodies for cancer therapy, Institut Curie

Favicon for changeflow.com ChangeBridge: Patent Grants - Peptides (C07K)
Published April 7th, 2026
Detected April 7th, 2026
Email

Summary

USPTO granted Patent US12594302B2 to Institut Curie covering fully humanized anti-FGFR4 single domain antibodies (sdAbs), functionalized drug nanocarriers, and compositions for cancer therapy. The patent includes 24 claims and covers nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The invention relates to FGFR4-targeted therapies for treating cancer.

What changed

USPTO granted Patent US12594302B2 to Institut Curie on April 7, 2026. The patent covers fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof, including functionalized drug nanocarriers, nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The application (No. 17925411, filed May 20, 2021) contains 24 claims related to cancer therapy compositions.

Patent owners and licensees may enforce exclusive rights against potential infringers developing similar FGFR4-targeted cancer therapies. Competitors should review the patent claims to assess potential licensing needs or design-around requirements before developing competing anti-FGFR4 antibody products. The patent provides Institut Curie with market exclusivity for the claimed antibody compositions and therapeutic uses.

Source document (simplified)

← USPTO Patent Grants

Single domain antibodies and their use in cancer therapies

Grant US12594302B2 Kind: B2 Apr 07, 2026

Assignee

Institut Curie

Inventors

Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia

Abstract

The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.

CPC Classifications

C07K 16/2863 A61K 40/31

Filing Date

2021-05-20

Application No.

17925411

Claims

24

View original document →

Named provisions

Anti-FGFR4 single domain antibodies Functionalized drug nanocarriers Cancer therapy compositions

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594302B2

Who this affects

Applies to
Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Biopharmaceutical Research Patent Licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Grants - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.